Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Unexplained fever and B-symptoms in a young male Black African].
Weber T, Ettrich T, Christopeit M, Lindner A, Holzhausen HJ, Oehme A, Arnold D, Wolf HH, Lübbert C, Kekulé AS, Schmoll HJ, Werdan K, Ebelt H. Weber T, et al. Among authors: ettrich t. Internist (Berl). 2012 Jan;53(1):93-8. doi: 10.1007/s00108-011-2912-6. Internist (Berl). 2012. PMID: 21953027 German.
Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.
Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, Niedermeier M, Müller L, Kubicka S, König A, Büchner-Steudel P, Wille K, Berger AW, Kestler AMR, Kraus JM, Werle SD, Perkhofer L, Ettrich TJ, Kestler HA. Seufferlein T, et al. Among authors: ettrich tj. PLoS One. 2024 Jun 14;19(6):e0304324. doi: 10.1371/journal.pone.0304324. eCollection 2024. PLoS One. 2024. PMID: 38875244 Free PMC article.
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. Türeci O, et al. Among authors: ettrich t. Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. Ann Oncol. 2019. PMID: 31240302 Free PMC article. Clinical Trial.
[Therapy in pancreatic cancer - and still it moves along!].
Ettrich TJ, Perkhofer L, Seufferlein T. Ettrich TJ, et al. Dtsch Med Wochenschr. 2015 Apr;140(7):508-11. doi: 10.1055/s-0041-101154. Epub 2015 Mar 31. Dtsch Med Wochenschr. 2015. PMID: 25826035 German.
Regorafenib.
Ettrich TJ, Seufferlein T. Ettrich TJ, et al. Recent Results Cancer Res. 2014;201:185-96. doi: 10.1007/978-3-642-54490-3_10. Recent Results Cancer Res. 2014. PMID: 24756792 Review.
Pancreatic Cancer: Progress in Systemic Therapy.
Perkhofer L, Ettrich TJ, Seufferlein T. Perkhofer L, et al. Among authors: ettrich tj. Gastrointest Tumors. 2014 May;1(4):167-79. doi: 10.1159/000380785. Epub 2015 Mar 27. Gastrointest Tumors. 2014. PMID: 26672477 Free PMC article. Review.
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.
Ettrich TJ, Perkhofer L, von Wichert G, Gress TM, Michl P, Hebart HF, Büchner-Steudel P, Geissler M, Muche R, Danner B, Kächele V, Berger AW, Güthle M, Seufferlein T. Ettrich TJ, et al. BMC Cancer. 2016 Jan 15;16:21. doi: 10.1186/s12885-016-2052-4. BMC Cancer. 2016. PMID: 26772812 Free PMC article. Clinical Trial.
97 results